Arcus Biosciences annual working capital
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences Working Capital Growth & History (RCUS)
Arcus Biosciences's working capital was $776.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $776.0M | −$14.0M | −1.77% |
| 2024 | 2024-12-31 | $790.0M | $143.0M | +22.10% |
| 2023 | 2023-12-31 | $647.0M | −$227.0M | −25.97% |
| 2022 | 2022-12-31 | $874.0M | −$222.0M | −20.26% |
| 2021 | 2021-12-31 | $1.10B | $481.9M | +78.46% |
| 2020 | 2020-12-31 | $614.1M | $444.1M | +261.26% |
| 2019 | 2019-12-31 | $170.0M | −$72.0M | −29.76% |
| 2018 | 2018-12-31 | $242.0M | $77.9M | +47.44% |
| 2017 | 2017-12-31 | $164.1M | — | — |
Arcus Biosciences quarterly working capital
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $558.0M | −$178.0M | −24.18% |
| Q1 2026 | 2026-03-31 | $635.0M | −$204.0M | −24.31% |
| Q4 2025 | 2025-12-31 | $776.0M | −$14.0M | −1.77% |
| Q3 2025 | 2025-09-30 | $622.0M | −$290.0M | −31.80% |
| Q2 2025 | 2025-06-30 | $736.0M | −$87.0M | −10.57% |
| Q1 2025 | 2025-03-31 | $839.0M | −$21.0M | −2.44% |
| Q4 2024 | 2024-12-31 | $790.0M | $143.0M | +22.10% |
| Q3 2024 | 2024-09-30 | $912.0M | $230.0M | +33.72% |
| Q2 2024 | 2024-06-30 | $823.0M | $17.0M | +2.11% |
| Q1 2024 | 2024-03-31 | $860.0M | $24.0M | +2.87% |
| Q4 2023 | 2023-12-31 | $647.0M | −$227.0M | −25.97% |
| Q3 2023 | 2023-09-30 | $682.0M | −$241.9M | −26.19% |
| Q2 2023 | 2023-06-30 | $806.0M | −$257.5M | −24.21% |
| Q1 2023 | 2023-03-31 | $836.0M | −$267.0M | −24.20% |
| Q4 2022 | 2022-12-31 | $874.0M | −$222.0M | −20.26% |
| Q3 2022 | 2022-09-30 | $923.9M | $521.5M | +129.59% |
| Q2 2022 | 2022-06-30 | $1.06B | $447.9M | +72.75% |
| Q1 2022 | 2022-03-31 | $1.10B | $393.2M | +55.39% |
| Q4 2021 | 2021-12-31 | $1.10B | $481.9M | +78.46% |
| Q3 2021 | 2021-09-30 | $402.4M | −$231.9M | −36.56% |
| Q2 2021 | 2021-06-30 | $615.6M | $184.0M | +42.64% |
| Q1 2021 | 2021-03-31 | $709.8M | $564.6M | +388.81% |
| Q4 2020 | 2020-12-31 | $614.1M | $444.1M | +261.26% |
| Q3 2020 | 2020-09-30 | $634.3M | $454.9M | +253.52% |
| Q2 2020 | 2020-06-30 | $431.6M | $230.4M | +114.48% |
| Q1 2020 | 2020-03-31 | $145.2M | −$80.8M | −35.75% |
| Q4 2019 | 2019-12-31 | $170.0M | −$72.0M | −29.76% |
| Q3 2019 | 2019-09-30 | $179.4M | −$69.2M | −27.84% |
| Q2 2019 | 2019-06-30 | $201.2M | −$49.8M | −19.85% |
| Q1 2019 | 2019-03-31 | $226.0M | −$41.8M | −15.61% |
| Q4 2018 | 2018-12-31 | $242.0M | $77.9M | +47.44% |
| Q3 2018 | 2018-09-30 | $248.7M | — | — |
| Q2 2018 | 2018-06-30 | $251.1M | — | — |
| Q1 2018 | 2018-03-31 | $267.8M | — | — |
| Q4 2017 | 2017-12-31 | $164.1M | — | — |
Arcus Biosciences working capital trends
Over the last five fiscal years, Arcus Biosciences's working capital increased from $614.1M to $776.0M, a change of $161.9M. The latest reported quarter, Q2 2026, shows $558.0M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
